Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totaling 5,123,769 shares, a growth of 100.8% from the April 15th total of 2,551,164 shares. Based on an average daily volume of 8 shares, the days-to-cover ratio is currently 640,471.1 days.
Idorsia Price Performance
IDRSF remained flat at $5.75 during trading hours on Friday. The firm’s 50 day moving average is $4.27 and its 200-day moving average is $4.50. Idorsia has a 1-year low of $1.68 and a 1-year high of $5.82.
About Idorsia
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
Featured Articles
- Five stocks we like better than Idorsia
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
